SCHEMBL7038765

SCHEMBL7038765

CSC1=NC(=O)C(=Cc2ccc(N3CCC4(CC3)OCCO4)cc2)S1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
ALDH1A1 P00352 3/20 0.54
GAA P10253 1/20 0.54
MYC P01106 1/20 0.51
MAX P61244 1/20 0.51
ALOX5 P09917 2/20 0.50
GRIN1 Q05586 1/20 0.43
GRIN2B Q13224 1/20 0.43
DCTPP1 Q9H773 1/20 0.43
RAB9A P51151 3/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
AVPR1A P37288 2/20 0.40
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PKM P14618 1/20 0.40
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7039412 0.84 ALOX5 (0.49) MAPTALDH1A1ALOX5GRIN1GRIN2B
SCHEMBL6876895 0.83 MEN1 (0.57) MAPTALDH1A1GAAALOX5GRIN1
SCHEMBL6876887 0.83 MEN1 (0.57) MAPTALDH1A1GAAALOX5GRIN1
SCHEMBL7214894 0.82 ENPP2 (0.57) MAPTALDH1A1ALOX5GRIN1GRIN2B
SCHEMBL6874189 0.82 ENPP2 (0.57) MAPTALDH1A1ALOX5GRIN1GRIN2B
SCHEMBL6876477 0.82 ALOX5 (0.47) MAPTALDH1A1ALOX5GRIN1GRIN2B
SCHEMBL6073902 0.80 MAPT (0.55) MAPTALDH1A1GAARAB9AKMT2A
SCHEMBL6073906 0.80 MAPT (0.55) MAPTALDH1A1GAARAB9AKMT2A
SCHEMBL6876281 0.79 ALOX5 (0.45) MAPTALDH1A1GAAALOX5GRIN1
SCHEMBL6876276 0.79 ALOX5 (0.45) MAPTALDH1A1GAAALOX5GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821991-B2 FOR THERAPY OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA (ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE), ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, FREQUENT URINATION WYETH 2004-11-23 US disclosed
US-20030176412-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists WYETH 2003-09-18 US disclosed
US-6583140-B2 Useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders WYETH 2003-06-24 US disclosed
US-20020169325-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists WYETH 2002-11-14 US disclosed
US-6410734-B1 INSULIN RESISTANCE; HYPOGLYCEMIC AGENTS; ANTICHOLESTEROL AGENTS; GASTROINTESTINAL DISORDERS WYETH 2002-06-25 US disclosed
WO-2002006281-A1 2-SUBSTITUTED THIAZOLIDINONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169325-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 MAPT 1197/4885ALDH1A1 447/4885GAA 1984/4885
US-20030176412-A1 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 MAPT 1197/4885ALDH1A1 447/4885GAA 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.